The HCPLive Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.
October 6th 2024
The rheumatology month in review emphasizes new trends in medication use and novel technologies' potential for managing fibromyalgia.
Collaborating Across the Continuum™: The Role of Multidisciplinary Care in the Management of Patients with Exocrine Pancreatic Insufficiency
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
October 26, 2024
Register Now!
6th Annual Advanced Practice Collaborative
View More
SimulatED™: Personalizing Treatment Choices to Achieve Glycemic and Weight Management Goals
View More
Cases and Conversations™: Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis
November 18, 2024
Register Now!
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Clinical ShowCase™: Forming a Personalized Treatment Plan for a Patient With ANCA-Associated Vasculitis
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
New Data Examines Mortality Risk and Allopurinol Use in Patients with Gout and CKD
January 24th 2022Contrary to recent research that indicated a higher risk of death associated with escalating doses of allopurinol for chronic kidney disease, investigators announce no association between allopurinol initiation and increased mortality among patients with gout and CKD.
Risankizumab Receives FDA Approval for Active Psoriatic Arthritis
January 24th 2022On Jan. 21, AbbVie announced the FDA granted approval to their IL-23 inhibitor risankizumab-rzaa (SKYRIZI) for treatment of active psoriatic arthritis in adult patients based on the results of the KEEPsAKE-1 and KEEPsAKE-2 trials.
Deucravacitinib Effectively Treats Moderate-to-Severe Plaque Psoriasis
Deucravacitinib selectively binds to a unique pocket in the regulatory domain of TYK2 instead of the highly conserved active site of the catalytic domain,” investigators explained. “This leads to targeted inhibition of immune pathways that are central to psoriasis while limiting off-target effects.”
Rheumatoid Arthritis Quiz: Physical Activity During the COVID-19 Pandemic
January 18th 2022Physical activity is known to improve function, quality of life, and pain in rheumatoid arthritis. How has the pandemic affected patients’ participation in physical activity? Test your knowledge with this quiz.
W. Benjamin Nowell, PhD: ArthritisPower Mobile App Identifies MTX-Related Side Effects
W. Benjamin Nowell, PhD, Director, Patient-Centered Research, CreakyJoints, discusses his study, "Patient-Reported Nausea and Fatigue Related to Methotrexate: A Prospective, Self-Controlled Study in the ArthritisPower® Registry.”
Younger Age Deemed Risk Factor of Flare in Patients Discontinuing Glucocorticoids
Patients with systemic lupus erythematosus who were younger in age or were serologically active yet clinically quiescent were more likely to have disease flare during glucocorticoid cessation.
COVID-19 Booster May Enhance T-cell Immune Response in Rituximab-Treated Patients With RA
While patients with rheumatoid arthritis on rituximab therapy have been reported to have insufficient serological responses to the COVID-19 vaccine, T cells, which protect against severe COVID-19, may be elevated after a third dose.
Efficacy and Safety of Tofacitinib Not Impacted by Dose-Switching
While patients with rheumatoid arthritis may benefit from either increasing or decreasing their dosage of tofacitinib, post-hoc analysis indicates that safety and efficacy of the medication is not impacted by these changes.